Gender disparities in the National Institutes of Health funding for gastrointestinal oncology. Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively ...

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group PURPOSE: To characterize the clinical and biologic features of ...